DLA Piper Strengthens Market-leading Corporate Team With Addition of Partner Josh Seidenfeld in Silicon Valley 
Life Biosciences Announces FDA Clearance of IND Application for ER-100 in Optic Neuropathies
IND clearance marks the first ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trialsBOSTON, Jan. 28,...
Cannara Announces Conditional Approval to List on the Toronto Stock Exchange
MONTREAL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQX: LOVFF)...
Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026
Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and...
OKYO Pharma Announces Successful Type C Meeting with the FDA
FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approachLONDON and NEW YORK, Jan. 28, 2026...
BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™...
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements...
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on...
OMass Therapeutics Appoints Jonathan Montagu as Chair of the Board of Directors
OXFORD, United Kingdom, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines...
Seamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing Loss
-- Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient...
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in...
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of...
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its...
Vireo Growth Inc. Enters into Non-Binding Memorandum of Understanding to Acquire The Hawthorne Gardening Company from ScottsMiracle-Gro
Planned share-based transaction is expected to be completed during the first fiscal quarter of 2026 Vireo plans to appoint Chris...
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a...
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
Nugevia™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss Jupiter, Florida, Jan. 28, 2026 (GLOBE NEWSWIRE) --...
Mabtech and Sai Life Sciences Announce Strategic Collaboration to Advance Immunology Research with EYRA Platform at Sai Boston Site
BOSTON and STOCKHOLM, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mabtech, a global life science tools company specializing in advanced immunoassays,...
DXS International plc (AQSE: DXSP): Half-year Financial Report
DXS INTERNATIONAL PLC (AQSE: DXSP) HALF YEAR RESULTS DXS International plc ("DXS" or the "Company"), the digital clinical decision support...
Newly published research further validates GlucoModicum’s path to high-precision, non-invasive glucose monitor
The study explains the mechanism behind up to 100× sensitivity amplification in glucose sensorsThe article was published in Biosensors and...
Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America
Ad hoc announcement pursuant to Art. 53 LR Regulatory dossier to obtain marketing authorization for QUVIVIQ has been submitted to...
HepatoBurn Investigated (SAFETY REPORT) Is This Liver Formula Legit? Side Effects, Risks, and Warnings Explained
Las Vegas, Nevada, Jan. 28, 2026 (GLOBE NEWSWIRE) -- If you are researching HepatoBurn reviews in 2026, you are not...